This week, Bryan Johnson published something most people have never seen: his own cells, reprogrammed back to a pluripotent state, sitting in a petri dish. He called it “baby-bryan.” Millions of people read it.

We were glad to see it. It is not every day that pluripotency trends on social media, and it is not every day that a mainstream audience encounters the idea that the body’s repair capacity might be restorable rather than simply managed. Credit where it is due.

He is right about the core science. Pluripotent cells can differentiate into a very wide range of cell types, and because they originate from the patient, immune rejection is not the barrier it would be with donor material. He is also right that pluripotent cells are worth taking seriously in autoimmune conditions.

There are two things worth adding. The first is a small, friendly correction about what is actually in that dish. The second is about method — and it is the difference between a milestone and a therapy.

First, the affectionate part: there is no baby in the dish

We say this warmly, because it is a lovely image and we understand why he reached for it. But a dish of pluripotent stem cells is not a small person, and it could not become one.

Here is why, in plain terms. In early development, the fertilized egg divides into a blastocyst — a hollow sphere with two distinct populations of cells. The outer layer, the trophectoderm, goes on to build the placenta and the supporting structures. The inner cell mass, tucked inside, is what becomes the body.

Pluripotent stem cells correspond to that inner cell mass. Only that. They can make every tissue of the body, which is extraordinary, but they cannot make the placenta or the supporting architecture a developing embryo depends on. Pluripotency is the capacity to become any cell type. It is not the capacity to become an organism.

So reprogramming an adult cell with Yamanaka factors resets the epigenetic clock — well or imperfectly, which we will come to — and produces a stem cell. A remarkable one. But a stem cell, not an embryo, and not a person in miniature. Those cells in the dish are a repair kit, not a passenger.

This distinction matters beyond semantics. It is precisely why pluripotent stem cell therapy is not the ethical minefield the public often assumes it is, and it is worth saying clearly whenever this science reaches a wide audience.

Second: how you make the cells determines how they behave

There is more than one way to return an adult cell to a pluripotent state. Over the past twenty years, our team has worked through the major routes.

• Yamanaka-factor reprogramming, which introduces defined transcription factors to reset cell identity. This produces induced pluripotent stem cells (iPSCs), and it is the method described in Johnson’s post.
• Small-molecule reprogramming, which attempts the same reset chemically.
• Somatic cell nuclear transfer (SCNT), in which the nucleus of an adult cell is placed into an enucleated oocyte, and the oocyte’s own cytoplasmic machinery performs the reset.

All three can produce cells that express pluripotency markers. They do not all produce cells that behave the same way in culture over time.

What the literature actually shows about iPSCs

The most useful summary of this remains Narsinh, Plews and Wu in Molecular Therapy (2011), which asked whether iPSCs and embryonic stem cells are fraternal or identical twins. Their answer was nuanced and worth reading in full.

Reported differentiation yields from iPSCs toward neural and cardiovascular lineages are lower and more variable than from embryonic lines, and iPSC-derived early blood progenitor and endothelial cells show signs of premature senescence. When the DNA methylome was compared at single-base resolution, roughly 45 percent of differentially methylated regions reflected a failure to fully erase the somatic cell’s epigenetic memory — while roughly 55 percent were patterns found in neither the starting cell nor in embryonic stem cells. Aberrations arising from the reprogramming process itself.

One detail deserves emphasis, because it is often misunderstood. This variability was observed regardless of whether reprogramming transgenes remained in the genome, and transgene-free iPSC lines still showed transcriptional differences from embryonic lines. The issue is therefore not simply that the DNA has been altered by the delivery method. The issue is that factor-driven reprogramming resets the epigenome incompletely and sometimes erratically — which means cleaner delivery does not resolve it.

To be fair to the field: the same body of work found no single deviation shared by all iPSC lines, and embryonic and induced lines are better described as two overlapping populations than as two separate categories. Some authors argue residual epigenetic memory can even be used deliberately to bias a line toward a desired lineage. This is a real and thoughtful counterpoint.

Our position is narrower and drawn from practice rather than polemic: when the goal is a stable autologous line that behaves predictably year after year, that variability is not an academic curiosity. It is the whole problem.

Why SCNT, and why the oocyte matters

SCNT takes a different approach. Rather than introducing factors, it places the adult nucleus into the environment that performs this reset in nature. The oocyte cytoplasm carries the complete remodeling machinery, and the epigenetic resetting it achieves is more thorough than what factor-based reprogramming typically produces.

Our protocol adds one further step. We generate the oocyte from the recipient’s own fibroblasts. In conventional SCNT, the mitochondria in the resulting cells come from the donor egg rather than the patient. By building the oocyte from the patient’s own cells, the mitochondrial DNA remains the patient’s throughout. The line is autologous in the complete sense — nuclear and mitochondrial alike.

As of today, we hold more than 150 patient-derived pluripotent lines in stable culture produced this way.

On the immune question

Johnson cited his autoimmune diagnosis as the reason he pursued this path, and that instinct is well founded. Pluripotent stem cells are not only a source of replacement tissue; they are immunologically active in their own right.

Work published in Transplantation Immunology (2011) found that embryonic stem cells suppressed both the proliferation and the survival of CD4+ T cells in vitro, and reduced secretion across a broad panel of cytokines including IL-2, IL-12, IFN-γ, TNF-α, IL-4, IL-5, IL-1β and IL-10. The effect was mediated primarily through direct cell-to-cell contact.

That study examined alloimmune rather than autoimmune response, and we want to scope it honestly rather than overstate it. But the mechanism it describes — direct modulation of T cell behavior — is the mechanism that matters in autoimmune presentations, and it is consistent with what we observe clinically.

Where this is heading

Johnson framed his diagnosis as the thing that opened this frontier for him. We understand that framing. Most of the patients who come to us arrive at the same door for the same reason.

What we would add is that the frontier is further along than the coverage suggests. The question is no longer whether adult cells can be returned to pluripotency. It is which method yields lines that remain stable, behave predictably, and can be worked with for years rather than months.

That is the work we have been doing since before it trended.

References

• Narsinh KH, Plews J, Wu JC. Comparison of human induced pluripotent and embryonic stem cells: fraternal or identical twins? Molecular Therapy. 2011;19(4):635–638. doi:10.1038/mt.2011.41 (PMC3070108)
• Kim EM, et al. Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response. Transplantation Immunology. 2011. doi:10.1016/j.trim.2011.05.004 (PMID 21635949)
• Bock C, et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell. 2011;144:439–452.
• Lister R, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature. 2011.